201 related articles for article (PubMed ID: 23679051)
41. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
42. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
43. Long-term survivors of glioblastoma: clinical features and molecular analysis.
Sonoda Y; Kumabe T; Watanabe M; Nakazato Y; Inoue T; Kanamori M; Tominaga T
Acta Neurochir (Wien); 2009 Nov; 151(11):1349-58. PubMed ID: 19730774
[TBL] [Abstract][Full Text] [Related]
44. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
45. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
46. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
47. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
49. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
50. Improved treatment of glioblastoma - changes in survival over two decades at a single regional Centre.
Eriksson M; Kahari J; Vestman A; Hallmans M; Johansson M; Bergenheim AT; Sandström M
Acta Oncol; 2019 Mar; 58(3):334-341. PubMed ID: 30732527
[TBL] [Abstract][Full Text] [Related]
51. Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C; Capellades J; Pineda E; Estival A; Puig J; Domenech S; Verger E; Pujol T; Martinez-García M; Oleaga L; Velarde J; Mesia C; Fuentes R; Marruecos J; Del Barco S; Villà S; Carrato C; Gallego O; Gil-Gil M; Craven-Bartle J; Alameda F;
Cancer Med; 2017 Dec; 6(12):2858-2866. PubMed ID: 29105360
[TBL] [Abstract][Full Text] [Related]
52. Survival Analysis of Glioblastoma Multiforme.
Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
[TBL] [Abstract][Full Text] [Related]
53. Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study.
Pan H; Alksne J; Mundt AJ; Murphy KT; Cornell M; Kesari S; Lawson JD
Med Oncol; 2012 Sep; 29(3):2040-5. PubMed ID: 22108847
[TBL] [Abstract][Full Text] [Related]
54. High levels of cellular proliferation predict pseudoprogression in glioblastoma patients.
Pouleau HB; Sadeghi N; Balériaux D; Mélot C; De Witte O; Lefranc F
Int J Oncol; 2012 Apr; 40(4):923-8. PubMed ID: 22086066
[TBL] [Abstract][Full Text] [Related]
55. Post progression survival in glioblastoma: where are we?
Franceschi E; Ermani M; Bartolini S; Bartolotti M; Poggi R; Tallini G; Marucci G; Fioravanti A; Tosoni A; Agati R; Bacci A; Pozzati E; Morandi L; Balestrini D; Ghimenton C; Crisi G; Brandes AA
J Neurooncol; 2015 Jan; 121(2):399-404. PubMed ID: 25366365
[TBL] [Abstract][Full Text] [Related]
56. Pseudoprogression of malignant glioma in Chinese patients receiving concomitant chemoradiotherapy.
Chan DT; Ng RY; Siu DY; Tang P; Kam MK; Ma BB; Wong GK; Ng SC; Pang JC; Lau CK; Zhu XL; Ng HK; Poon WS
Hong Kong Med J; 2012 Jun; 18(3):221-5. PubMed ID: 22665686
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for glioblastoma therapy associated complications.
Ening G; Osterheld F; Capper D; Schmieder K; Brenke C
Clin Neurol Neurosurg; 2015 Jul; 134():55-9. PubMed ID: 25942630
[TBL] [Abstract][Full Text] [Related]
58. Olfactory function as an independent prognostic factor in glioblastoma.
Kebir S; Hattingen E; Niessen M; Rauschenbach L; Fimmers R; Hummel T; Schäfer N; Lazaridis L; Kleinschnitz C; Herrlinger U; Scheffler B; Glas M
Neurology; 2020 Feb; 94(5):e529-e537. PubMed ID: 31831598
[TBL] [Abstract][Full Text] [Related]
59. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Ogura K; Mizowaki T; Arakawa Y; Ogura M; Sakanaka K; Miyamoto S; Hiraoka M
Radiat Oncol; 2013 Apr; 8():97. PubMed ID: 24499582
[TBL] [Abstract][Full Text] [Related]
60. Differentiation of true-progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide by GLCM texture analysis of conventional MRI.
Chen X; Wei X; Zhang Z; Yang R; Zhu Y; Jiang X
Clin Imaging; 2015; 39(5):775-80. PubMed ID: 25956436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
